About Us

Back to About Us

David Gortler PharmD, FCCP

Associate Scholar

David Gortler PharmD, FCCP is a scholar at the Ethics and Public Policy Center in Washington, D.C. focusing on FDA oversight and drug safety.  Previously he worked at the U.S. Food and Drug Administration as a Senior Medical Analyst from 2007-2011, and as senior advisor to the FDA commissioner from 2019-2021. He is assisting the Charlotte Lozier Institute as an FDA drug safety and FDA regulatory affairs expert.

Dr. Gortler is comprehensively reviewing several of the FDA/White House’s initiatives to debase the REMS safety/public health standards for pharmaceuticals protecting women’s health.  During Dr. Gortler’s time at the Agency, he directly advised the FDA commissioner’s office on regulatory action supporting the Emergency Use Authorization of two mRNA vaccines against Covid-19, both in a record timeframe and in an extremely challenging environment.

Dr. Gortler is a principled and resolute advocate of science-based decision making, as well as an advocate for federal healthcare oversight, which include finding market solutions to drug pricing and healthcare access for all Americans. In addition to his public service, Dr. Gortler has extensive academic experience, having served as a professor of pharmacology at Yale University School of Medicine and Georgetown University School of Medicine. He earned his Pharm.D. from the University of Arizona, did his postdoctoral fellowship at the Yale University School of Medicine in pharmacology and molecular biology, and did a clinical residency through the Columbia – New York Presbyterian hospital system.  Read David Gortler’s full bio here.

Latest Research & News

  • Questions and Answers on Late-Term Abortion | May 16, 2022

    First published: February 2019 Last updated: May 16, 2022   To view this fact sheet as a PDF, see: Fact Sheet: Questions and Answers on Late-Term Abortion   What is a Late-Term Abortion?   “Late-term” abortion is an imprecise term, but under any “formal” definition offered or as accepted by the public at large late-term […]